ODAN K-8 Potassium Chloride 600 mg (8 mEq) Slow Release Tablets
ODAN K-8 Potassium Chloride 600 mg (8 mEq) Slow Release Tablets, NPN 80008214: natural health product licensed in Canada. Medicinal ingredients: Chlorure de potassium.
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Chlorure de potassium Potency : 8 mEq | 600 mg | Not calculated |
Non-medicinal ingredients
Ethylcellulose, Talc, Oxydes de fer, Poly(sorbate) 80, Poly(alcool vinylique), Acide stéarique, Poly(éthylène glycol), Dioxyde de titane, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | minimum: 3 days ; maximum: 5 days |
| Adultes | Not specified | 2 Comprimé | minimum: 3 days ; maximum: 6 days |
Uses authorised in Canada
Treatment or prevention of hypokalemia (potassium depletion) which does not result from dietary deficiency. Potassium replacement therapy. Electrolyte replenisher. For the treatment of metabolic alkalosis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
For therapeutic use only. To be taken only on the advice of a physician. Take this medicine immediately after meals or with food to lessen possible stomach upset or laxative action. A probable association exists between the use of coated tablets containing potassium salts, with or without thiazide diuretics, and the incidence of serious small bowel ulceration. Such preparations should be used only when adequate dietary supplementation is not practical, and should be discontinued if abdominal pain, distention, nausea, vomiting or gastrointestinal bleeding occur.
Product record
- Licence holder
- Odan Laboratories Ltd.
- NPN or DIN-HM
- 80008214
- Status
- Active licence
- Licence date
- 21 October 2008
- Revision date
- Not provided
- Form
- Comprimé à libération prolongée
- Route of administration
- Orale
- Application type
- TPD Cat IV/LS
Source
Official Health Canada record, licence 80008214
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “ODAN K-8 Potassium Chloride 600 mg (8 mEq) Slow Release Tablets (Odan Laboratories Ltd.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80008214-odan-k-8-potassium-chloride-600-mg-8-meq-slow-release-tablet, updated 21 October 2008.